cas 218594-79-7|| where to buy (S)-3-(Hydroxymethyl)morpholine Hydrochloride

Название продукции:(S)-3-(Hydroxymethyl)morpholine Hydrochloride

IUPAC Name:[(3S)-morpholin-3-yl]methanol hydrochloride

Упаковочная единица	Доступно для заказа	Цена ($)
CM116109-1g	in stock	ƥǪ
CM116109-5g	in stock	Ǫƥľ
CM116109-10g	in stock	ƿǙŗ
CM116109-25g	in stock	ƥƥƥ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 218594-79-7 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:218594-79-7; Молекулярная формула:C5H12ClNO2; Точка плавления:-; Smiles-код:OC[C@@H]1NCCOC1.[H]Cl; Плотность:

: Номер в каталоге:CM116109; Молекулярная масса:153.61; Точка кипения:; Номер Mdl:MFCD12547468; Хранение:Store at 2-8°C.

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Elinzanetant; On January 8, 2024, Bayer announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully met all four primary endpoints and all three key secondary endpoints in both studies. Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist for the non-hormonal treatment of moderate to severe VMS associated with menopause. Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen, become hypertrophic and lead to a hyperactivation of the thermoregulatory pathway, consequently disrupting body heat control mechanisms resulting in VMS. Elinzanetant may also decrease sleep disturbances associated with menopause.